Brachytherapy

In the 1960’s, the permanent insertion of radioactive material into the prostate gland developed. Doctors tried the interstitial insertion of gold -198 or Iodine - 125 seeds into the prostate gland in conjunction with EBRT. Unfortunately, the success of these techniques was poor due to the inability to see the prostate gland and the surrounding organs. Not until around 1980’s, when doctors began to use a transperineal needle temple, transperineal needles, and the transrectal ultrasound, did Brachytherapy become a viable prostate cancer treatment.

Types Of Prostate Brachytherapy

There are two types of Brachytherapy that are used in the treatment of prostate cancer: Permanent Low Dose Radiation (LDR) and Temporary High Dose Radiation (HDR).

LDR Brachytherapy uses iodine -125 and palladium -103 stored in titanium cases, usually referred to as Brachytherapy Seeds. As the name Permanent Brachytherapy suggest, the seeds are permanently left inside the prostate gland. Over the course of their radioactive lives, the seeds will continuously emit low levels of radiation.

HDR Brachytherapy uses a single radioactive seed made of iridium -194, which is sometimes referred to as an iridium wire. Soft flexible plastic catheters are inserted through the perineum, and into the prostate gland. HDR Brachytherapy entails an overnight stay in the hospital, during which a patient undergoes two or three treatments with the wire through each catheter.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

PCF BC

Ride to Live 2018 and 50-50 Draw: May 27

The West Coast Motorcycle Ride to Live, raising funds for Prostate Cancer Foundation BC, takes place on Sunday May 27, 2018 in Vancouver, Victoria & the Fraser Valley. Follow the links to join a ride or donate to a rider; or to buy a ticket for a 50/50 draw (BC residents only).

Employment

Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.